Information Provided By:
Fly News Breaks for January 18, 2018
INSM
Jan 18, 2018 | 08:47 EDT
Credit Suisse analyst Martin Auster started Insmed with a Neutral rating and $31 price target, stating that he assumes ALIS will launch around the end of 2018 with a price near the top end of anti-infective therapies but he prefers to wait for a firmer sense of how the drug will be deployed by doctors.
News For INSM From the Last 2 Days
There are no results for your query INSM